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The spatial organization and the antigenic structure of the bacteriorhodopsin molecule in the purple mem- 
brane were studied by immunochemical techniques. Five monoclonal antibodies directed against exposed 
parts of the protein molecule in the membrane were prepared and characterized. Antigenic determinants 
were localized in the bacteriorhodopsin polypeptide chain by analysis of the interaction between monoclonal 
antibodies and protein fragments. The structure of antigenic determinants was revealed by the interaction 
of monoclonal antibodies with (i) isolated bacteriorhodopsin fragments further modified by sequential Ed- 
man degradation and (ii) derivatives of bacteriorhodopsin obtained biosynthetically or by selective chemical 
modification., Five antigenic determinants were localized in the following parts of bacteriorhodopsin: 
< Gh~l-Met*~ involving one of the 3 amino acid residues of the N-terminal part; Gly33-Met56 involving Asp36 
and/or Asp3* and Phe4*; PherS6-Met163 involving PherS6; Glur%-LeuZo7 involving GlulW; Prozoo-LeuZo7. 
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1. INTRODUCTION 
Bacteriorhodopsin (BR) is a retinal-containing 
chromoprotein from purple membranes (PM) of 
Halobacterium halobium (reviews [1,2]). Its com- 
plete amino acid sequence [3,4] and general scheme 
of arrangement of the polypeptide chain in the 
membrane [5] have been established. Several 
models [2,6,7] have been proposed to describe the 
fine structure of the BR molecule in membranes, 
i.e., to define which regions of the polypeptide 
chain are intramembranous and which are exposed 
on the cell surface. These models are based on the 
identification of exposed amino acid residues using 
partial proteolytic cleavage of the polypeptide 
chain [&IO] and selective chemical or enzymatic 
modifications [ 11,131. 
Monoclonal antibodies (mAb) represent a 
powerful new tool for the investigation of the 
structure and function of membrane proteins 
[14,15]. We have prepared a set of mAbs directed 
against the BR molecule, and used them to study 
the BR structure and topography in the PM 
[16,17]. The results obtained permit us to refine 
the chromoprotein topography and identify amino 
acid residues essential for interaction with par- 
ticular mAbs. 
2. MATERIALS AND METHODS 
BR was isolated according to [18]. Fluorinated 
BR analogs were prepared as described in [19]. 
Chymotrypsin cleavage of the polypeptide chain 
into fragments 1-71 and 72-248 (C-2 and C-l) and 
subsequent separation of the fragments as well as 
delipidation were carried out as in [20]. 
Chromatography on Sephadex LH-60 was per- 
formed in nonaqueous olvents [18]. To cleave the 
polypeptide chain at bond Gly155-Phe’56 [ 181, 
NaBH4 was added to a suspension of PM 
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(1.5 mg/ml) in 0.05 M NH4HCO3, pH 10.0, up to 
a final concentration of 3% and stirred for 24 h at 
4°C in the dark. After centrifugation (4 times) in 
HzO, the membranes were treated with papain to 
remove C-terminal fragment 232-248 .[8]. Peptide 
156-231 was isolated by Sephadex LH-60 
chromatography in 98% formic acid-absolute 
ethanol (3:7). Peptide 156-231 was cleaved with 
BNPS-skatole as in [21], then fragments 156-182, 
183- 189 and 190-23 1 were separated on Sephadex 
LH-20 and LH-60. Homogeneity of isolated BR 
fragments was confirmed by amino acid and N- 
terminal analyses. Localization of the regions tof 
the polypeptide chain cleaved with NaBH4 or 
BNPS-skatole was supported by the Edman 
degradation of peptides 156-231 and 190-231, 
respectively. 
Papain cleavage of BR in PM was carried out ac- 
cording to [8]. To modify carboxyl groups [22], the 
PM (1 mg/ml) were dissolved in 5 ml of 0.2 M 
sodium phosphate buffer, pH 4.75, containing 
2 M ethylenediamine, and 1-ethyl-3-(3-dimethyl- 
aminopropyl)carbodiimide was added to a final 
concentration of 0.4 M. The pH value was careful- 
ly controlled as carbodiimide was added over a 1 h 
interval and the reaction allowed to proceed for a 
further 5 h. After the reaction was completed, the 
membranes were spun down in water. The limited 
acid hydrolysis of BR fragment 1-71 was per- 
formed as follows: peptide 1-71 (8 nmol) was 
dissolved in 0.06 N HCl, containing 40% 
CHKOOH and hydrolysed for 22 h at 105’C 
under vacuum. The acid was then evaporated off. 
The reaction products were analyzed by polyacryl- 
amide gel electrophoresis in the presence of SDS 
~231. 
Preparation of hybridomas, cloning and screen- 
ing of positive clones were carried out as in [24,25]. 
To obtain preparative amounts of mAbs, 
hybridomas were grown in mice of the correspon- 
ding strain or in a culture by means of rollers. 
mAbs were isolated and purified either using am- 
monium fractionation followed by ion-exchange 
chromatography, or by affinity chromatography 
on protein A-Sepharose. The purified mAbs were 
characterized by polyacrylamide gel elec- 
trophoresis [23] and by isoelectric focusing [26]. 
The enzyme-linked immunoadsorbent assay 
(ELISA) was employed for screening hybridomas 
and for studying the antigenic structure of BR. Af- 
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finity purified rabbit antibodies to mouse im- 
munoglobulins, conjugated with horseradish 
peroxidase were applied as the developing reagent. 
The isotype of heavy chains and types of light 
chains were determined using conjugates of goat 
antibodies to isotypes of mouse immunoglobulins. 
50,ul aliquots of the PM suspension (1 mg protein 
per ml) were placed in each well of a 96-well plate, 
incubated for 1 h and then washed thoroughly 
with phosphate buffer containing 0.05% Tween 
20. The supernatant, ascites fluid or purified mAbs 
were added, incubated overnight at 4°C and 
washed out; finally, substrate (5-aminosalicylic 
acid or o-phenylenediamine) was added and the 
reaction allowed to proceed. When using the 
delipidated protein or peptides as antigen, the pro- 
cedure was changed slightly. The delipidated pro- 
tein was sonicated in distilled water at a protein 
concentration of 1 mg/ml and 50 ~1 of this suspen- 
sion was added to the wells. Incubation was carried 
out for 1 h and further steps were as described 
above. Cyanogen bromide fragments dissolved in 
formic acid were placed into the wells containing 
20~1 of the acid, dried by vacuum, treated with 
PBS and tested as described above. 
3. RESULTS AND DISCUSSION 
We have recently prepared and characterized 60 
hybridomas producing antibodies to bacteriorho- 
dopsin [ 16,171. Five of them secreting mAbs 
against exposed regions of the polypeptide chain 
were chosen for further study. The properties of 
these mAbs are listed in table 1. 
To define epitopes of BR, recognized by these 
mAbs, the interaction of mAbs with fragments of 
BR was studied using ELISA. The fragments were 
obtained by cyanogen bromide, BNPS-skatole or 
proteolytic cleavage of BR and taken together 
covered the whole length of the polypeptide chain 
(table 2). The results are summarized in table 3. 
mAb IDzGr interacts with the fragments Bl, C2 
and BrCN-2; consequently, the epitope they 
recognize must be situated within the BrCN-2 frag- 
ment (residues l-20). mAb HsEs interacts with Bl, 
C2 and BrCN-1 fragments; so, the corresponding 
epitope must be located within the BrCN-1 frag- 
ment (residues 33-56). mAb Ar4H3 interacts only 
with fragments B2 and (BrCN-7 + BrCN-ll), 
which have overlapping region Phe1s6-Met163; the 
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Table 1 
Monoclonal antibodies against bacteriorhodopsin 
January 1985 
No. Code of Antigen used Strain of mice Myeloma cells Type of mAb Ka (M-‘1 
hybridoma for immuniza- 
tion 
1 ID2G1 
2 I-I& 
3 AI.+H~ 
4 IDzRl 
5 HsF3 
a See table 2 
C! F, (B/c.B1/6) Ag8.653 -63 YI k 2 x108 
BR BALB/c Ag8.653.63 YI k 5 x108 
BR BALB/c Ag8.653.63 YI k 1.5 x lo8 
BNPS-skatol F,(B/c . Bl/6) Ag8.653.63 yzak 6 x108 
BR BALB/c Ag8.653.63 YI k 9 x10’ 
Each K, was calculated on the basis of a Scatchard plot 
Table 2 
Fragments of bacteriorhodopsin used for the study of 
antigenic specificity of monoclonal antibodies 
No. Designation of Region of the 
fragment BR polypeptide chain 
1 BI < Glu’-Gly’” 
2 I32 Phe’56-Gly23’ 
3 CZ < Glur-Phe’r 
4 BrCN-1 Gly33-Met56 
5 BrCN-2 < Glu’-Met2’ 
6 BrCN-3 Gly2’-Met32 
7 BrCN-6 Va12’0-Ser248 
8 (BrCN-7 + BrCN-11) Ile”9-Met’63 
9 BrCN- 10 Gly72-Met”8 
10 BrCN-9 Arg r”_Met209 
11 BNPS-skatol Leu’“-Gly23’ 
corresponding epitope is most likely located within 
this region. The two other antibodies HsF3 and 
IDzRI interact with fragments BrCN-9 and 
BNPS-1, overlapping in the region Leu190-Met209; 
therefore, corresponding epitopes are located 
within this region. The results of this study are 
shown schematically in fig. 1. 
To define more precisely the structure of the 
epitopes, derivatives of BR or its fragments were 
obtained and their interactions with mAbs were 
investigated. 
Treatment of PM with ethylenediamine in the 
presence of water-soluble carbodiimide drastically 
decreased binding of mAb HsEs without any in- 
fluence on interaction of PM with mAbs IDzGr, 
Ar4H3 and HsF3 (table 4). Only carboxylic groups 
(Asp or Glu) should be modified under these con- 
Table 3 
Interaction of monoclonal antibodies with fragments of bacteriorhodopsin 
No. mAb Binding of monoclonal antibodies to different antigens Region of BR poly- 
peptide chain contain- 
PM BO Br Cz BrCN-1 BrCN-2 Bz BrCN- BrCN-7 BrCN-9BrCN-6 BNPS- ing antigenic 
10 BrCN- skatol determinant 
11 
1 IDzGr + + + + - + - - _ - - - < Glu’-Met” 
2 H5E5 + + + + - _ - - - Gly33-Met56 
3 A,4H3 + + - - - - + - + - - - Phe”6-Met163 
4 IDzR, + + - - - _ + - _ + - + Leu’“-Met209 
5 H5F3 + + - - - - + - - + - + Leu’90-Met209 
The interaction of mAbs with the purple membrane (PM), bacterioopsin (BO) and fragments of BR (see table 2) was 
tested by ELISA; ( + ) positive interaction, ( - ) negative interaction 
345 
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Fig. 1. Localization of antigenic determinants of bacteriorhodopsin by means of overlapping fragments. The fragments 
are listed in table 2; ID&i, H5E5, Ar4H3, IDzRr and H5F3 are monoclonal antibodies (table 1); (m) regions of 
polypeptide chain within which antigenic determinants are located. 
Table 4 
Influence of selective chemical, biosynthetic and proteolytic modifications of bacteriorhodopsin on the binding of 
monoclonal antibodies 
No. Modification of BR Interaction of BR derivatives 
with monoclonal antibodies 
ID2G H5Es AI~H~ IDzRl HsF3 
Essential residue 
constituting antigenic 
determinant 
1 Cleavage of as residues l-3 + _ _ - - (<Glu’; Ala’; 
with papain Gln3) 
2 Modification of as residues Asp _ + - + - As~‘~/Asp~~ 
and Glu with ethylenediamine Gl~‘~~/Glu~~ 
3 Biosynthetic modification of bacterio- 
rhodopsin by replacement of Phe 
with F-Phe _ + + _ _ Phe42; Phe’56 
4 Biosynthetic modification of 
bacteriorhodopsin by replacement 
of Trp with F-Trp - - - - - _ 
(+) Modification caused the inhibition of the interaction of mAb with the BR derivatives; (-) no inhibition 
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ditions. Within region 33-56 where the epitope for 
mAb HSES is located, the only carboxylic groups 
are those of Asp36 and Asp3*. Consequently, one 
or both of these residues must be the constituent 
part of the antigenic determinant. To prove this 
suggestion, fragment C2 (l-7 1) was quantitatively 
cleaved by partial acid hydrolysis into peptides 
with an apparent molecular mass of 3 kDa. The N- 
terminal analysis showed the splitting of bond 
Asp36-Pro37. The mixture of these peptides in- 
teracted with mAb HsEs much less effectively than 
original fragment 1-71, while the interaction with 
mAb IDzGr was unaffected by acid hydrolysis of 
the C2 fragment. The observed inhibition of bind- 
ing of mAb IDzRr after modification of acidic 
groups in BR implicates glutamic acid residues 194 
and 204 in the binding site, since mAb ID2Ri is 
directed against region 190-209. 
LETTERS January 1985 
mAb ID2Gi interaction with PM was completely 
abrogated after treatment of membranes with pa- 
pain (as in [8]), resulting in cleavage of regions 
l-3, 66-72 and 232-248 from the protein 
molecule (table 4). Since, as shown above, the 
epitope for mAb IDzGi is located within the region 
l-20, this result means that at leasts one of 3 
removed residues, <Glu’, Ala2 or Gln3, is a part of 
the epitope. 
Region Leu’90-Met209 includes epitopes for 
mAbs HsFs and ID2Rt. To identify the composi- 
tion of these epitopes the interaction of mAbs with 
truncated peptides was studied. Such peptides were 
obtained by the stepwise Edman degradation of 
the BNPS-1 fragment (190-231), beginning with 
Leti”’ and up to Pro”‘. Binding of mAb IDzRi 
was drastically decreased after removal of Glu’” 
(fig.2a) but removal of Leu190-Pro200 residues did 
I I02Rl --_ c-I”“““’ 
0 
Leu-lie-Gly-Ser-Glu-Gly-Ala_Gly-I~e-~l-pro N- termtml seq&e of 
80 191 I92 193 1% 195 196 197 I96 199 200 BNps-j h- 
100 
b 
* 
N-temwd sequence of 
B2 fragment 
Fig.2. Influence of the truncation of bacteriorhodopsin fragments on the interaction with monoclonal antibodies. 
Truncation was carried out by sequential Edman degradation of the fragments of bacteriorhodopsin. (A) Interaction 
of mAbs HsFs and IDzRr with the truncated fragments of BNPS-1 
truncated fragments of B2 (Phels6- 
(LeulgO 
GIY~~‘). 
-GIY~~‘); (B) interaction of mAb Ar4H3 with 
The vertical direction shows binding of mAb with shortened fragments after 
removal of certain residues as measured by ELISA; the horizontal direction shows the amino acid sequence of 
fragments. 
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not affect the interaction of the shortened peptides 
with mAb HsF3. So the antigenic determinant for 
mAb IDzRi includes Glu ‘%, while the epitope for 
mAb HsF3 is situated nearer to the C-terminal part 
of the molecule, within the region Pro200-Met209. 
A similar approach was used for identification 
of the residues constituting the epitope recognized 
by mAb Ai4H3. In the course of the Edman 
degradation of the B2 fragment, the inhibition of 
binding of the mAb was observed immediately 
after the removal of residue Phels6 (fig.2). Thus, 
residue Phe156 is the essential one in the antigenic 
determinant recognized by mAb A14H3. 
Biosynthetically fluorinated analogs of BR, 
similar to the natural chromoprotein in the struc- 
tural and functional properties [19], were used for 
further identification of the structure of antigenic 
determinants. Replacement of 56% of Phe 
residues with 3-F- or 4-F-Phe caused reduction of 
binding of mAb Ai4H3 and HsEs to PM by 57%, 
whereas the interaction with the 3 other mAbs re- 
mained the same (table 4). Therefore, Phe residues 
appear to be essential in the antigenic determinants 
for these two mAbs. In the case of mAb AidH3, 
this result correlates with the data shown above, 
which also places Phe’56 in the epitope for mAb 
Ai4H3. In the case of mAb HsE5 residue Phe42 
located in the vicinity of residues As~~~/Asp~~ 
(discussed above) may be included in the epitope. 
These data also imply that residue PheZo* is not in- 
cluded in the antigenic determinant of mAb HsF3. 
Table 5 
Location and composition of antigenic determinants of 
bacteriorhodopsin 
No. Region of poly- Essential amino Code 
peptide containing acid residues of mAb 
antigenic 
determinant 
1 l- 20 < C&r’-Gln3 ID&l 
2 33- 56 A~p~~/Asp~~, Phe4’ HsE5 
3 83-118 
a 
4 156-163 Phe’56 AI& 
5 194-207 Glu’” I&RI 
6 200-207 - I&F3 
7 232-248 Ala246_Ser24s a 
a Data from Kimura et al. [27] 
348 
Hence, this determinant appears to be located 
within region 200-207, rather than in 200-209. 
PM with the 95% substitution of 5-F-Trp for 
Trp residues bind all mAbs with the same efficien- 
cy as the native PM. This means that tryptophan 
residues either are not involved in any epitope 
studied, or are not essential for the interaction of 
mAbs with PM. If the first assumption is correct, 
the epitope for mAb ID2Gi does not include the 
Trp” residue and appears to be located within 
region l-9. It should be mentioned that similar 
results were obtained by modification of Lys 
residues, which also did not influence the interac- 
tion of mAbs H5Es and Ai4Hs with PM (not 
shown). 
The data on the location of epitopes of BR and 
their composition are summarized in table 5. 
Together with data obtained earlier by Kimura et 
al. [27], our findings revealed the presence of 8 se- 
quential antigenic determinants in the BR 
molecule. These determinants are located in the 
central, N- and C-terminal regions of the molecule. 
It is of note that most epitopes, studied by us and 
Kimura et al. [27], contain Asp or Glu residues. 
Apparently, negatively charged amino acid 
residues of BR are essential for interaction with 
antibodies. 
As mentioned above, all mAbs studied can bind 
to PM. Consequently, the corresponding epitopes 
must be exposed on the membrane surface. The 
location of N-terminal fragment l-3 and region 
162-163 as antigenic determinants correlates with 
previous data concerning exposure of amino acid 
residues [ 1,3], whereas the localization of residues 
As~~~/Asp~*, Phe42, G~u’~~ and region 200-207 
(or part of it) on the surface of the membrane is 
shown here for the first time. 
Thus the presence of exposed regions within se- 
quences 4-65 and 156-23 1 predicted earlier have 
received experimental support. Together with the 
previous data about exposed regions within se- 
quences 66-72 and 231-248 [8], this means that 
each sequence 4-65 and 156-231 contains two 
transmembrane segments. The topography of BR 
according to these findings is shown in fig.3. 
Of special interest is the exposure of residue 
Cil~‘~~ and the region belonging to sequence 
200-207, since this allows the identification of the 
boundaries of the C-terminal transmembrane seg- 
ment. The topography of this region is of 
Volume 179, number 2 FEBS LETTERS January 1985 
Fig.3. Location of antigenic determinants and to 
ArdH3, HsF3, IDzRI - monoclonal antibodies; 
as revealed by mAbs IDzGI, HsE5, 
essential amino acid residues; K, antigenic sites determined 
significance as Lys2r6 is the retinal attachment site. 
The spatial disposition of retinal is undoubtedly 
very important in vectorial proton transfer across 
the membrane. Neutron diffraction [28], 
fluorescence [29,30] and the analysis of photoin- 
duced cross-linking [7] do not allow the une- 
quivocal positioning of retinal in relation to the 
outer and inner membrane surface. In particular, 
photoinduced cross-links were identified between 
the photoactivable aromatic analog of retinal and 
residue GIu’~~, which was assumed to be inside the 
membrane according to the recently proposed 
model [7]. Our data, in contrast, indicate the ex- 
posure of the GIu’~~ residue on the surface, and in 
this respect support the earlier models [3]. Evident- 
ly, further investigations are necessary in order to 
establish the topography of Zhe polypeptide chain 
and chromophore of BR. Here the application of 
monoclonal antibodies can undoubtedly be of 
significance. 
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